The lack of the small protein interferon-β (IFNβ),which is involved in cell signaling and is integral in the body’s natural defense mechanism against viral infections, can compromise brain function in patients with HIV, according to a study published in the journal Brain Behavior and Immunity.
Advertisement
Delaying treatment for SAA until genetic testing for IBMFS may be detrimental in patients with negative workup and history.
Kavita Mistry and Marcelle Tuttle will be the American Kidney Fund 2024 Clinical Scientist in Nephrology Fellows.
Soft tumor environments can cause triple-negative breast cancer to spread more aggressively.
Darwin Kwok discusses how he felt about winning the award and what he’s learned from past recipients.
Older dialysis-dependent patients are at high risk of low bone mass associated with primary osteoporosis, CKD-MBD, or both.
Research is lacking on the longer-term outcomes of patients who develop pregnancy-related ESKD.
Immunoscore also showed prognostic benefit in DNA mismatch repair proficient disease.
Vertex Pharmaceuticals will acquire Alpine Immune Sciences, developer of povetacicept for IgA nephropathy.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Immunoscore also showed prognostic benefit in DNA mismatch repair proficient disease.
The study’s primary end points were objective response rate, overall survival, and safety.
Patients with a DpR of ≥30% had a favorable survival time with nivolumab monotherapy as a later-line treatment.
Dr. William Jarnagin discusses his recent study on characterizing the heterogeneity of intrahepatic cholangiocarcinoma.
For those with a PD-L1 CPS of 5 or higher who received the combination therapy, the median OS was not achieved.
This approval marks the first tumor-agnostic approval of a HER2-directed therapy.
The Latest From Heme Today
Delaying treatment for SAA until genetic testing for IBMFS may be detrimental in patients with negative workup and history.
Dr. Ansong-Ansongton shared what National Minority Health Month and Celebrate Diversity Month mean to him at ASPHO 2024.
Dr. Ansong-Ansongton described data on the impact of abnormal mitochondrial retention and cold in red blood cells in SCD.
Dr. Mamauag details her study on the need for factor VIII infusions in patients with tolerized hemophilia A on emicizumab.
The MAA for RP-L102, an investigational gene therapy for Fanconi anemia, has been approved by the EMA.
Dr. Sharathkumar shared data from her 2024 ASPHO presentation on romiplostim in children with severe aplastic anemia and MDS.
